The $1.81bn in venture capital invested in US biotech firms during the first quarter of 2016 was the sixth highest quarterly total ever, but with 118 companies raising VC cash, it was far from the highest number of deals in any given quarter, according to the MoneyTree Report from the National Venture Capital Association (NVCA) and PricewaterhouseCoopers based on Thomson Reuters data that goes back to 1995. And despite the large dollar volume raised by biotechs during the first three months of this year, only $359.1m was labeled as a "first sequence" investment, which was lower than any quarter in 2015.
Biotech VC Funding Rises As Fewer Companies Get More Dollars
Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.
More from Business
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from Scrip
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.